Published on 13 Nov 2023 on Zacks via Yahoo Finance
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $0.86 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 10.66%. A quarter ago, it was expected that this company would post a loss of $1.26 per share when it actually produced a loss of $1.27, delivering a surprise of -0.79%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.